Baize Medical (02609.HK) Popular Stock Analysis Report

Baize Medical (02609.HK) is a Chinese private oncology medical group, ranking 4th in China in terms of oncology service revenue in 2023, and 1st in early cancer screening centers and number of gastroscopy cases[1]. The stock recently made it to the Hong Kong Stock Market Popularity List on the East Money App, mainly because its price is close to the 52-week low (HKD 5.01), triggering attention and bottom-fishing speculative sentiment among retail investors[4].

As of December 4, 2025, 16:31, the stock price was HKD 5.090, down 0.050 (-0.973%) from the previous trading day[1]. The 52-week price range is HKD 5.01-HKD 19.88[1], indicating significant price volatility. The 10-day average trading volume is approximately 28.93 million shares[2], but the volume on December 3, 2025, was only 4.82 million shares, below the average[3].

1. Even though the company has a certain market position in the oncology medical service sector, its stock price has plummeted from HKD 19.88 to near HKD 5.01 within 52 weeks, a drop of over 74%, reflecting market concerns about its fundamentals.
2. The stock made it to the East Money App’s popularity list mainly due to its price being close to the 52-week low, not because of a clear positive catalyst[4]; the popularity in this case may be short-term speculative.
3. The low trading volume (only 4.82 million shares on December 3, 2025) indicates great divergence among market participants and a lack of clear direction[3].

• Risks
  :
  • The company is in a loss position, with an EPS of -0.02 in 2024[1].
  • The price-to-book ratio (P/B) is as high as 4.46, far exceeding the reasonable valuation range for loss-making companies[1].
  • High price volatility: the 52-week high and low differ by nearly 3 times[1].
  • No major news or announcements driving the stock price up have been found recently[5].
• Opportunities
  :
  • The price is close to the 52-week low, which may attract some bottom-fishing investors[1].
  • The company has a relatively high market position in the oncology medical service sector; if it can improve profitability in the future, it may bring valuation repair opportunities.

Baize Medical (02609.HK) is a company with a certain market position in the oncology medical service sector, but currently faces risks such as losses, high valuation, and price volatility. The stock made it to the popularity list mainly because its price is close to the 52-week low, not due to a clear positive catalyst. When investors pay attention to this stock, they should focus on the performance of support levels (HKD 5.01) and resistance levels (HKD 5.14, HKD 5.68), as well as changes in trading volume.